176 reports of this reaction
1.5% of all SEVOFLURANE reports
#18 most reported adverse reaction
RHABDOMYOLYSIS is the #18 most commonly reported adverse reaction for SEVOFLURANE, manufactured by AbbVie Inc.. There are 176 FDA adverse event reports linking SEVOFLURANE to RHABDOMYOLYSIS. This represents approximately 1.5% of all 11,848 adverse event reports for this drug.
Patients taking SEVOFLURANE who experience rhabdomyolysis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RHABDOMYOLYSIS is a less commonly reported adverse event for SEVOFLURANE, but still significant enough to appear in the safety profile.
In addition to rhabdomyolysis, the following adverse reactions have been reported for SEVOFLURANE:
The following drugs have also been linked to rhabdomyolysis in FDA adverse event reports:
RHABDOMYOLYSIS has been reported as an adverse event in 176 FDA reports for SEVOFLURANE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RHABDOMYOLYSIS accounts for approximately 1.5% of all adverse event reports for SEVOFLURANE, making it a notable side effect.
If you experience rhabdomyolysis while taking SEVOFLURANE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.